Additionally, this study demonstrated that GITR is mainly highly expressed in tumor-infiltrating Tregs, while low expression is found in CD8+ T cells, macrophages, naive T cells, etc. Tumor-infiltrating (Ti)-Tregs were considered a preferable potential target for DTA-1 treatment [81]. Here, CD8A is linked to neoplasm.